LAUSR

e18–e47. 2. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ; IPF Consensus Working Group. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018;51:1800692. 3. Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, SchlenkerHerceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 2020;55:2000085. 4. Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med 2020;383:958–968. 5. Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The burden of progressive-fibrosing interstitial lung diseases. Front Med (Lausanne) 2022;9:799912. 6. Latsi PI, du Bois RM, Nicholson AG, Colby TV, Bisirtzoglou D, Nikolakopoulou A, et al. Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531–537. 7. Jegal Y, Kim DS, Shim TS, Lim C-M, Do Lee S, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639–644. 8. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733–748. 9. Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritisassociated interstitial lung disease. Eur Respir J 2016;47:588–596. 10. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69:1670–1678. 11. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al.; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381:1718–1727. 12. Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al.; INBUILD trial investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020;8: 453–460. 13. Nasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J 2021;57:2002718. 14. Takei R, Brown KK, Yamano Y, Kataoka K, Yokoyama T, Matsuda T, et al. Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype. Respirology 2022;27:333–340. 15. Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C, et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J [online ahead of print] 10 Mar 2022; DOI: 10.1183/13993003.02571-2021. 16. Oldham JM, Lee CT, Wu Z, Bowman WS, Pugashetti JV, Dao N, et al. Lung function trajectory in progressive fibrosing interstitial lung disease. Eur Respir J 2022;59:2101396. 17. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, et al.; Erice ILD working group. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med 2020;8:925–934. 18. Johannson KA, Kolb M, Fisher JH, Walsh SL. Progressive pulmonary fibrosis: putting the cart before the horse. Am J Respir Crit Care Med 2022;206:1294–1295. 19. Pugashetti JV, Adegunsoye A, Wu Z, Lee CT, Srikrishnan A, Ghodrati S, et al. Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med 2023;207:69–76. 20. Khor YH, Farooqi M, Hambly N, Kolb M, Ryerson CJ, Austin ILD; Austin ILD Registry and CARE-PF Investigators. Patient characteristics and survival for progressive pulmonary fibrosis using different definitions. Am J Respir Crit Care Med 2023;207:102–105. 21. Maher TM, Brown KK, Kreuter M, Devaraj A, Walsh SLF, Lancaster LH, et al.; INBUILD trial investigators. Effects of nintedanib by inclusion criteria for progression of interstitial lung disease. Eur Respir J 2022;59:2004587. 22. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med 2020;8:147–157. 23. Behr J, Prasse A, Kreuter M, Johow J, Rabe KF, Bonella F, et al.; RELIEF investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021;9:476–486.